NeuroOne(NMTC)

Focus: NeuroOne is a public biotechnology company specializing in cortical electrode technology for neurological applications. The company operates at a modest commercial scale with $3M in FY 2025 revenue.

Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About NeuroOne

AI assessmentNot Hiring

No open roles listed right now. Follow NeuroOne to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$3M

FY2025

Pipeline & Clinical Trials

Participants are not assigned an intervention as part of the study.

Drug Resistant Epilepsy

N/A

Clinical Trials (1)

NCT07546253Post-Market Real-World Evidence Registry for the NeuroOne OneRF® Ablation System for Epilepsy

N/A

Help build intelligence for NeuroOne

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage medical device innovator with focus on high-value cortical electrode technology in underserved neurology space
Public company status provides equity upside potential and institutional stability vs. private venture-backed peers
R&D-heavy model (147% R&D intensity) signals commitment to innovation over near-term profitability

Watch Out For

Severe cash burn ($12.3M net loss in FY 2025) with only $1M cash on hand creates existential funding risk within 1-2 quarters
Zero active clinical trials, no pipeline programs, and no marketed products indicate commercialization is years away with uncertain probability of success
No open job requisitions and declining R&D spend ($7M to $5M YoY) suggest potential workforce contraction or capital preservation mode

Generated by Claude from NeuroOne's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 1 clinical trial

Top TAs: Neurology

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Neurology

1 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$3M77%

R&D Spend

$5M(147%)27%

Net Income

-$12M